The slightly longer survival times of LDH-A KD CT2A and ALTS1C1 tumors compared to NC controls is also consistent with our previous findings with 4T1 breast and MyC-CaP prostate tumors [18,19]. The gene discussed is MYC; the disease is prostate neoplasm.